Login to Your Account



Zealand/Sanofi's Lixisenatide as Effective as Lilly's Byetta

By Nuala Moran


Wednesday, February 9, 2011
LONDON – Zealand Pharma A/S advanced its hopes of delivering the second once-daily glucagon-like peptide-1 agonist (GLP-1) to the market, announcing the results from a Phase III trial comparing its product lixisenatide to exenatide (Byetta), which is administered twice daily. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription